-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Sanofi And Regeneron Present New Dupixent Results Highlighting Disease Severity Reduction In Patients With Darker Skin Tones

Benzinga·06/09/2025 07:03:44
Listen to the news
  • Atopic dermatitis is a chronic disease that disproportionately impacts communities of color
  • Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients
  • Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline
  • Results support commitment to enhance clinical understanding of chronic diseases in communities of color